Drug lookup
Drug reference

phytonadione

Vitamin K · Vitamin supplement

Vitamin KVitamin supplement
CDSCO approved
EXCRETION
not curated
INTERACTIONS
none in our sources
PREGNANCY
not curated

Mechanism

Phytonadione is Vitamin K1, an essential cofactor in the γ-carboxylation of multiple glutamate residues of clotting factors (II, VII, IX, X) and anticoagulant proteins (C, S, Z). It promotes the biosynthesis of these factors, which are necessary for blood coagulation.

Indications

correction of bleeding tendency or hemorrhage associated with vitamin K deficiencyreversal of warfarin effectshypoprothrombinemia of the newbornbiliary obstructionmalnutritionProphylaxis and treatment of bleeding due to vitamin K deficiencyDietary vitamin K deficiencyProlonged antimicrobial therapyObstructive jaundiceMalabsorption syndromes (sprue, regional ileitis, steatorrhoea)Newborn hypoprothrombinemia (prevention of haemorrhagic disease of the newborn)Overdose of oral anticoagulantsProlonged high dose salicylate therapy (prophylaxis of hypoprothrombinemia)

Dosing

Adult
For prolonged intravenous alimentation, 1 mg per week (equivalent of about 150 μg/day) to prevent hypoprothrombinemia. For biliary obstruction or fistula, 10 mg daily. For hepatocellular disease or long-standing biliary obstruction, 10 mg daily parenterally.
Pediatric
Routine administration of 1 mg intramuscularly at birth for hypoprothrombinemia of the newborn. Dose may need to be increased or repeated if mother received warfarin or anticonvulsant therapy, or if infant develops a bleeding diathesis.
Renal adjustment
In severe hepatitis or cirrhosis (associated with inadequate utilization), large doses of vitamin K or its analogues can paradoxically contribute to a further reduction in prothrombin levels.

Pharmacokinetics

Onset
rapidly corrects hypoprothrombinemia in the neonate, controlling bleeding within about 6 hours
Protein binding
Only temporarily concentrated in liver, no significant body stores.
Metabolism
incorporated into chylomicrons and associated with triglycerides and lipoproteins after absorption
Excretion
concentrated in the liver, but concentration declines rapidly

Contraindications

  • rapid intravenous infusion (can cause severe reactions resembling anaphylaxis)
  • subcutaneous route in patients with a coagulopathy (due to risk of bleeding)

Side effects

Serious
  • hemolytic anemia (with synthetic forms in neonates)
  • kernicterus (with synthetic forms in neonates)
  • Severe anaphylactoid reactions (on i.v. injection of emulsified formulation)
  • Haemolysis (with menadione and water-soluble derivatives, especially in G-6-PD deficient patients and neonates)
  • Kernicterus (with menadione/its salts in newborns)

Related guidelines

Ask House about phytonadione

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team